{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:01:27Z","timestamp":1777910487481,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:46:30Z","timestamp":1719096390000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Biologic anti-IL17 drugs in erythrodermic psoriasis"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7404-3807","authenticated-orcid":false,"given":"Alessandro","family":"Falco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mugheddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Anedda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pizzatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Tatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunella","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdin.2024.05.007_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0190-9622(08)80643-3","article-title":"Erythrodermic psoriasis","volume":"24","author":"Brenner","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2024.05.007_bib2","first-page":"93","article-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Liao","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jdin.2024.05.007_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/CCID.S121302","article-title":"Systemic abnormalities of psoriatic patients: a retrospective study","volume":"9","author":"Yin","year":"2016","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jdin.2024.05.007_bib4","first-page":"59","article-title":"Updates on the treatment of erythrodermic psoriasis","volume":"11","author":"Lo","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"10.1016\/j.jdin.2024.05.007_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.05.007_bib6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjd.16252","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2024.05.007_bib7","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1111\/jdv.14234","article-title":"Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis","volume":"31","author":"Mugheddu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2024.05.007_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2024.05.007_bib9","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.jid.2016.07.008","article-title":"IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis","volume":"136","author":"Xing","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2024.05.007_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.05.007_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/jcm8060770","article-title":"Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study","volume":"8","author":"Damiani","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jdin.2024.05.007_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12607","article-title":"Erythrodermic psoriasis and secukinumab: our clinical experience","volume":"31","author":"Mateu-Puchades","year":"2018","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdin.2024.05.007_bib13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.12773","article-title":"Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis","volume":"29","author":"Saeki","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2024.05.007_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jdv.15416","article-title":"Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients","volume":"33","author":"Egawa","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2024.05.007_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jdv.15287","article-title":"Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)","volume":"33","author":"Okubo","year":"2019","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"5","key":"10.1016\/j.jdin.2024.05.007_bib16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.16497","article-title":"Ixekizumab or secukinumab in psoriasis: what difference does it make?","volume":"178","author":"Paul","year":"2018","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2024.05.007_bib17","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1111\/jdv.18069","article-title":"Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis","volume":"36","author":"Avallone","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jdin.2024.05.007_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.18174","article-title":"Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series","volume":"181","author":"Lo","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.05.007_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13348","article-title":"Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab","volume":"33","author":"Pizzatti","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jdin.2024.05.007_bib20","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/1346-8138.14649","article-title":"Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab","volume":"46","author":"Shibata","year":"2019","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2024.05.007_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13632","article-title":"Covid-19 and exacerbation of psoriasis","volume":"33","author":"Ozaras","year":"2020","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.jdin.2024.05.007_bib22","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1111\/jdv.17582","article-title":"Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre","volume":"35","author":"Sotiriou","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:59:58Z","timestamp":1740887998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":22,"alternative-id":["S2666328724000919"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.05.007","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic anti-IL17 drugs in erythrodermic psoriasis","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}